NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
Reading CABR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CABR free→QuarterlyIQ Insights · CABR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 30% of the time over the next year (vs 50% for the rest of the cohort, n=9274).
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
